Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma

  • García-Domínguez, D. J.
  • Hajji, Nabil
  • Sánchez-Molina, Sara
  • Figuerola-Bou, Elisabet
  • Martínez de Pablos, Rocío
  • Espinosa-Oliva, Ana M.
  • Andrés-León, Eduardo
  • Terrón-Camero, Laura Carmen
  • Flores-Campos, Rocío
  • Pascual-Pasto, Guillem
  • Robles-Frías, María José
  • Machado, Isidro
  • Llombart-Bosch, Antonio
  • Magagnoli, Giovanna
  • Scotlandi, Katia
  • Carcaboso, Ángel M.
  • Mora, Jaume
  • Álava, Enrique de
  • Hontecillas-Prieto, Lourdes
Ewing sarcoma (EWS) is an aggressive bone and soft tissue tumor of children and young adults in which the principal driver is a fusion gene, EWSR1-FLI1. Although the essential role of EWSR1-FLI1 protein in the regulation of oncogenesis, survival, and tumor progression processes has been described in-depth, little is known about the regulation of chimeric fusion-gene expression. Here, we demonstrate that the active nuclear HDAC6 in EWS modulates the acetylation status of specificity protein 1 (SP1), consequently regulating the SP1/P300 activator complex binding to EWSR1 and EWSR1-FLI1 promoters. Selective inhibition of HDAC6 impairs binding of the activator complex SP1/P300, thereby inducing EWSR1-FLI1 downregulation and significantly reducing its oncogenic functions. In addition, sensitivity of EWS cell lines to HDAC6 inhibition is higher than other tumor or non-tumor cell lines. High expression of HDAC6 in primary EWS tumor samples from patients correlates with a poor prognosis in two independent series accounting 279 patients. Notably, a combination treatment of a selective HDAC6 and doxorubicin (a DNA damage agent used as a standard therapy of EWS patients) dramatically inhibits tumor growth in two EWS murine xenograft models. These results could lead to suitable and promising therapeutic alternatives for patients with EWS., Research in the E.D.A. lab is supported by Asociación Española Contra el Cáncer (AECC), the Ministry of Science of Spain-FEDER (CIBERONC, PI1700464, PI2000003, RD06/0020/0059)S. D.G.D. and L.H.P. are supported by CIBERONC (CB16/12/00361). D.G.D., M.J.R. and L.H.P. are PhD researchers funded by the Consejería de Salud, Junta de Andalucía (PI-0197-2016, ECAI F2-0012-2018 and PI-0013-2018, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation

  • Delgado-Bellido, Daniel
  • Oliver, Francisco Javier
  • Vargas Padilla, María Victoria
  • Lobo Selma, Laura
  • Chacón-Barrado, Antonio
  • Díaz-Martín, J.
  • Álava, Enrique de
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Tumor growth depends on the vascular system, either through the expansion of blood vessels or novel adaptation by tumor cells. One of these novel pathways is vasculogenic mimicry (VM), which is defined as a tumor-provided vascular system apart from endothelial cell-lined vessels, and its origin is partly unknown. It involves highly aggressive tumor cells expressing endothelial cell markers that line the tumor irrigation. VM has been correlated with high tumor grade, cancer cell invasion, cancer cell metastasis, and reduced survival of cancer patients. In this review, we summarize the most relevant studies in the field of angiogenesis and cover the various aspects and functionality of aberrant angiogenesis by tumor cells. We also discuss the intracellular signaling mechanisms involved in the abnormal presence of VE-cadherin (CDH5) and its role in VM formation. Finally, we present the implications for the paradigm of tumor angiogenesis and how targeted therapy and individualized studies can be applied in scientific analysis and clinical settings., E.d.Á. laboratory is supported by ISCIII-FEDER (PI20/00003, and PMP22/00054) to E.d.Á., Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018) to E.d.Á. and (PI-0061-2020) to E.d.Á., ECAEC222952DEAL, Fundación Científica AECC to E.d.Á, GEIS-Fundación Mari Paz Jiménez Casado (Beca Trienal a la Investigación en Sarcomas) to J.D.-M., Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC. This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, the Spanish Ministry of Science and Technology RTI2018-098968-B-I00, CIBERONC ISCIII CB16/12/00421 and Junta de Andalucía, a project of Excellence from Junta de Andalucía P10-CTS-0662, P12-CTS-383 to F.O. Fundación Domingo Martínez to F.O. Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_ 21_00865) to D.D.-B. Fundación Getthi ONC18PE01/2022 to E.d.Á., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism

  • Olmedo-Pelayo, Joaquín
  • Granado-Calle, Esperanza
  • Delgado-Bellido, Daniel
  • Lobo Selma, Laura
  • Jordán-Pérez, Carmen
  • Monteiro-Amaral, Ana T.
  • Ehlers, Anna C.
  • Ohmura, Shunya
  • García-Domínguez, Daniel
  • Mackintosh, Carlos
  • Carcaboso, Ángel M.
  • Alonso García de la Rosa, Francisco Javier
  • Machado, Isidro
  • Llombart-Bosch, A.
  • Scotlandi, Katia
  • Grünewald, Thomas G. P.
  • Gómez-Herreros, Fernando
  • Álava, Enrique de
Drug resistance is an ill-defined cause of dismal outcomes in cancer. Ewing sarcoma (EwS), a pediatric cancer characterized by high therapy failure rates, is driven by a single oncogenic event generating EWSR1::ETS gene fusions (primarily EWSR1::FLI1) in a silent genomic background. This provides a straightforward model to study the impact of gene fusions on drug responses. Here, we describe a novel mechanism of sensitivity to DNA topoisomerase 1 poisons in EwS. We discovered that EWS::FLI1 prevents the resolution of R-loops induced by these drugs via sequestering DHX9 helicase, ultimately resulting in R-loop accumulation, replication stress, and genome instability. In turn, excessive DHX9 or reduced EWS::FLI1 levels render EwS cells resistant to the active metabolite of irinotecan (SN-38) independent of proliferation and global transcription rates. This resistance helps explain how elevated DHX9 levels predict worse clinical outcomes. Overall, our research demonstrates the impact of a dominant mutation on cancer drug sensitivity, highlighting its significant clinical implications., JO-P is supported by Ph.D. grant Plan Propio from the University of Seville. DD-B is supported by Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_21_00865). DJG-D was supported by the VII Plan Propio de Investigación y Transferencia de la Universidad de Sevilla [Contrato de Acceso (II.4)/VII PPIT-US]. The laboratory of JA is supported by Instituto de Salud Carlos III (grant numbers PI20CIII/00020, DTS22CIII/00003, PMP21-00073); Asociación Pablo Ugarte (TRPV205/18, DGDO195722); Asociación Candela Riera, Asociación Todos Somos Iván & Fundación Sonrisa de Alex (TVP333-19, TVP-1324/15). The laboratory of TGPG is supported by grants from the Matthias-Lackas Foundation, the Dr. Leopold und Carmen Ellinger Foundation, the Deutsche Forschungsgemeinschaft (DFG 458891500), the German Cancer Aid (DKH-7011411, DKH-70114278), the Boehringer-Ingelheim foundation, the Dr. Rolf M. Schwiete foundation, the SMARCB1 association, the Ministry of Education and Research (BMBF; SMART-CARE and HEROES-AYA) and the Barbara and Wilfried Mohr foundation. A.C.E. was supported by a scholarship from the German Cancer Aid. The laboratory of FG-H is supported by grants funded by MCIN/AEI/10.13039/501100011033/FEDER, UE (R + D + i PID2019-105212GB-I00 and PID2022-137143NB-I00) and the Andalusian Regional Government: Fondo Europeo de Desarrollo Regional (FEDER) y Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (P20_00561) to FG-H. The laboratory of EdA is supported by grants from ISCIII-FEDER (PI20/00003, PI23/1460 and PMP22/00054), Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018, PI-0061-2020), Fundación Científica AECC (ECAEC222952DEAL), Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC Instituto de Salud Carlos III, CB16/12/00361., Peer reviewed